Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Atish Choudhury

Dana-Farber Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (8)

Karla Ballman

Chair / Consultant / Professor of Biostatistics

Mayo Clinic College of Medicine and Science

UNITED STATES

View details

Edoardo Francini

Associate Professor

The University of Iowa

UNITED STATES

View details

Peter Park

Harvard University

UNITED STATES

View details

David Yang

Dana-Farber Cancer Institute

UNITED STATES

View details

Ruolin Liu

Broad Institute

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jessica Hawley

Assistant Professor

University of Washington

UNITED STATES

View details

Brian C. Baumann

Washington University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Atish Choudhury

Research Interests

Explore related searches

Articles (20)

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)

A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer

A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).

Cell-free DNA nucleosome and genomic signatures as predictors of outcomes with radium-223 in metastatic castration-resistant prostate cancer.

Comeback from long-course ADT with relugolix (rel) and darolutamide (daro) in hormone-sensitive prostate cancer (PC) (CLEARED).

Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer

DirectHRD enables sensitive scar-based classification of homologous recombination deficiency

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer

Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes

Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer

Publsiher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer (Prostate Cancer and Prostatic Diseases, (2025), 10.1038/s41391-025-01049-5)

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Collaborators (8)

Karla Ballman

Edoardo Francini

Peter Park

David Yang

Ruolin Liu

Timothy Yap

Jessica Hawley

Brian C. Baumann

Make your next move.